Last reviewed · How we verify
VERDYE powder for solution for injection 25 mg
VERDYE, a 25 mg powder for solution for injection, is currently marketed by Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León. The key composition patent for VERDYE is set to expire in 2028, providing a clear period of exclusivity. The primary risk is the potential for increased competition post-patent expiry, which could impact market share and revenue.
At a glance
| Generic name | VERDYE powder for solution for injection 25 mg |
|---|---|
| Also known as | Indocyanine green (ICG) |
| Sponsor | Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: